Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part B: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part C: To test the safety and tolerability of combination therapy with Niraparib, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.

Part D: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.

Part E: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part F: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part G: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part H: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part I: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
Neoplasms|Metastatic Cancer|Advanced Cancer|Solid Tumor|Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Stage IIIB|Non Small Cell Lung Cancer
DRUG: Niraparib|DRUG: TSR-042|DRUG: Carboplatin-Paclitaxel|DRUG: Bevacizumab|DRUG: TSR-022|DRUG: Carboplatin-Pemetrexed|DRUG: Carboplatin-Nab-Paclitaxel
Part A: Number of Participants With Dose-limiting Toxicity (DLT), An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for \>=7 days from the time of adverse event(AE) onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for \>=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for \>=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (\>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish recommended phase 2 dose (RP2D)., 21 days|Part B: Number of Participants With DLT, An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for \>=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for \>=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for \>=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (\>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D., 21 days|Part C: Number of Participants With DLT, An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for \>=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for \>=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for \>=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (\>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D., 21 days|Part D: Number of Participants With DLT, An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for \>=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for \>=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for \>=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (\>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D., 21 days|Part E: Number of Participants With DLT, An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for \>=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for \>=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for \>=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (\>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D., 21 days|Part F: Number of Participants With DLT, An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for \>=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for \>=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for \>=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (\>2 weeks) in initiating Cycle 2. DLTs were collected during first cycle to establish RP2D., 21 days|Part G: Number of Participants With DLT, An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for \>=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for \>=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for \>=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (\>2 weeks) in initiating Cycle 2. DLTs were planned to be collected during first cycle to establish RP2D., 21 days|Part H: Number of Participants With DLT, An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for \>=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for \>=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for \>=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (\>2 weeks) in initiating Cycle 2. DLTs were planned to be collected during first cycle to establish RP2D., 21 days|Part I: Number of Participants With DLT, An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of following DLT criteria:hematologic toxicity- Grade4 thrombocytopenia persists for \>=7 days from the time of AE onset, Grade 4 neutropenia, Grade 4 or Grade 3 febrile neutropenia persists for \>=7 days, Grade4 or Grade3 anemia requiring blood transfusion, Grade 3 thrombocytopenia associated with clinically significant bleeding, Grade 3 neutropenia associated with infection as described in CTCAE version 4.0, drug related Grade 3 or 4 non-hematologic toxicity, drug related Grade 3 or 4 nonhematologic laboratory abnormality if any of the following also occur: abnormality leads to hospitalization and abnormality persists for \>=7 days from the time of AE onset; drug related toxicity leading to prolonged delay (\>2 weeks) in initiating Cycle 2. DLTs were planned to be collected during first cycle to establish RP2D., 21 days|Part A: Number of Participants With Non-serious Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs) and Adverse Events of Special Interest (AESIs), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported., Up to 28.5 months|Part B: Number of Participants With Non-serious TEAEs, STEAEs and AESIs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported., Up to 28.5 months|Part C: Number of Participants With Non-serious TEAEs, STEAEs and AESIs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported., Up to 22.5 months|Part D: Number of Participants With Non-serious TEAEs, STEAEs and AESIs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported., Up to 9.5 months|Part E: Number of Participants With Non-serious TEAEs, STEAEs and AESIs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported., Up to 4.4 months|Part F: Number of Participants With Non-serious TEAEs, STEAEs and AESIs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Number of participants with TEAEs, SAEs and AESIs are reported., Up to 3.5 months|Part G: Number of Participants With Non-serious TEAEs, STEAEs and AESIs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment., Up to 24 months|Part H: Number of Participants With Non-serious TEAEs, STEAEs and AESIs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment., Up to 24 months|Part I: Number of Participants With Non-serious TEAEs, STEAEs and AESIs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose; results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgement. TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment., Up to 24 months
Part A: Objective Response Rate, Objective Response Rate is defined as the percentage of participants who achieved confirmed complete response (CR) or partial response (PR), evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeters (mm) in the short axis. PR=At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters., Up to 28.5 months|Part B: Objective Response Rate, Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters., Up to 28.5 months|Part C: Objective Response Rate, Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters., Up to 22.5 months|Part D: Objective Response Rate, Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters., Up to 9.5 months|Part E: Objective Response Rate, Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters., Up to 4.4 months|Part F: Objective Response Rate, Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters., Up to 3.5 months|Part G: Objective Response Rate, Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters., Up to 24 months|Part H: Objective Response Rate, Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters., Up to 24 months|Part I: Objective Response Rate, Objective Response Rate is defined as the percentage of participants who achieved confirmed CR or PR, evaluated using RECIST version 1.1 based on Investigator assessment; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters., Up to 24 months|Part A: Duration of Response, Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause., Up to 28.5 months|Part B: Duration of Response, Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause., Up to approximately 66 months|Part C: Duration of Response, Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause., Up to approximately 60 months|Part D: Duration of Response, Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause., Up to approximately 62.5 months|Part E: Duration of Response, Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause., Up to 4.4 months|Part F: Duration of Response, Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause., Up to 3.5 months|Part G: Duration of Response, Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause., Up to 24 months|Part H: Duration of Response, Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause., Up to 24 months|Part I: Duration of Response, Duration of response is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST version 1.1 or death by any cause., Up to 24 months|Part A: Disease Control Rate, Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or stable disease (SD) per RECIST version 1.1., Up to 28.5 months|Part B: Disease Control Rate, Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1., Up to 28.5 months|Part C: Disease Control Rate, Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1., Up to 22.5 months|Part D: Disease Control Rate, Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1., Up to 9.5 months|Part E: Disease Control Rate, Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1., Up to 4.4 months|Part F: Disease Control Rate, Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1., Up to 3.5 months|Part G: Disease Control Rate, Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1., Up to 24 months|Part H: Disease Control Rate, Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1., Up to 24 months|Part I: Disease Control Rate, Disease Control Rate is defined as the percentage of participants who had achieved CR, PR, or SD per RECIST version 1.1., Up to 24 months|Part A: Progression-free Survival, Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study., Up to 28.5 months|Part B: Progression-free Survival, Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study., Up to 28.5 months|Part C: Progression-free Survival, Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study., Up to 22.5 months|Part D: Progression-free Survival, Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study., Up to 9.5 months|Part E: Progression-free Survival, Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study., Up to 4.4 months|Part F: Progression-free Survival, Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study., Up to 3.5 months|Part G: Progression-free Survival, Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier., Up to 24 months|Part H: Progression-free Survival, Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier., Up to 24 months|Part I: Progression-free Survival, Progression-free Survival is defined as the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier., Up to 24 months|Part A: Number of Participants With Positive Anti-TSR-042 Antibodies, Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay). Anti-drug Antibody Population consisted of all participants who received at least 1 dose of study treatment and had provided a pre-dose blood sample and at least 1 post-dose blood sample at or after 96 hours., Up to 28.5 months|Part B: Number of Participants With Positive Anti-TSR-042 Antibodies, Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 28.5 months|Part C: Number of Participants With Positive Anti-TSR-042 Antibodies, Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 22.5 months|Part D: Number of Participants With Positive Anti-TSR-042 Antibodies, Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 9.5 months|Part E: Number of Participants With Positive Anti-TSR-042 Antibodies, Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 4.4 months|Part F: Number of Participants With Positive Anti-TSR-042 Antibodies, Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 3.5 months|Part F: Number of Participants With Positive Anti-TSR-022 Antibodies, Serum samples were collected at indicated time points and tested for the presence of antibodies that bind to TSR-022. The presence of anti-TSR-022 antibodies were assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 3.5 months|Part G: Number of Participants With Positive Anti-TSR-042 Antibodies, Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were planeed to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 24 months|Part H: Number of Participants With Positive Anti-TSR-042 Antibodies, Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were planned to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 24 months|Part H: Number of Participants With Positive Anti-TSR-022 Antibodies, Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-022. The presence of anti-TSR-022 antibodies were planned to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 24 months|Part I: Number of Participants With Positive Anti-TSR-042 Antibodies, Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-042. The presence of anti-TSR-042 antibodies were planned to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 24 months|Part I: Number of Participants With Positive Anti-TSR-022 Antibodies, Serum samples were planned to be collected at indicated time points and tested for the presence of antibodies that bind to TSR-022. The presence of anti-TSR-022 antibodies were planned to be assessed using a tiered approach using electrochemiluminescence (that is, screening, confirmation, titer, and neutralizing antibody assay)., Up to 24 months|Part A: Area Under the Plasma Concentration From Time Zero to t (AUC[0-t]) of Niraparib, Blood samples were collected at indicated time points. Pharmacokinetic (PK) parameters of niraparib were calculated using non-compartmental methods. PK population consisted of all participants who received at least 1 dose of study treatment and had at least 1 PK sample., Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part A: AUC(0-t) of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part B: AUC0-t of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part C: AUC0-t of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part C: AUC0-t of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part D: AUC0-t of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part E: AUC0-t of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days)|Part F: AUC0-t of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: AUC0-t of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: AUC0-t of TSR-042, Blood samples were planned to be collected at indicated time points., Cycles 1 and 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days)|Part H: AUC0-t of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: AUC0-t of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: AUC0-t of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: AUC0-t of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part A: Area Under the Plasma Concentration From Time Zero to Infinity (AUC[0-infinity]) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part A: AUC(0-infinity) of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part B: AUC(0-infinity) of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part C: AUC(0-infinity) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part C: AUC(0-infinity) of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part D: AUC(0-infinity) of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part E: AUC(0-infinity) of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days)|Part F: AUC(0-infinity) of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: AUC(0-infinity) of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part G: AUC(0-infinity) of TSR-042, Blood samples were planned to be collected at indicated time points., Cycles 1 and 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days)|Part H: AUC(0-infinity) of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: AUC(0-infinity) of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: AUC(0-infinity) of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: AUC(0-infinity) of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part A: Observed Concentration at the End of the Dosing Interval (Ctau) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part A: Ctau of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part B: Ctau of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part C: Ctau of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part C: Ctau of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part D: Ctau of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part E: Ctau of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Ctau of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Ctau of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: Ctau of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Ctau of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part H: Ctau of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part I: Ctau of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part I: Ctau of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part A: Maximum Observed Plasma (Cmax) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part A: Cmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part B: Cmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part C: Cmax of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part C: Cmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part D: Cmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part E: Cmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Cmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Cmax of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part G: Cmax of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Cmax of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part H: Cmax of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part I: Cmax of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part I: Cmax of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part A: Clearance After Oral Administration (CL/F) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part A: Clearance After Intravenous Administration (CL) of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part B: CL of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part C: CL/F of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part C: CL of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part D: CL of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part E: CL of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days)|Part F: CL of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: CL of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: CL of TSR-042, Blood samples were planned to be collected at indicated time points., Cycles 1 and 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days)|Part H: CL of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: CL of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: CL of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: CL of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part A: Volume of Distribution After Oral Administration (Vz/F) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part A: Volume of Distribution After Intravenous Administration (Vz) of of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part B: Vz of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part C: Vz/F of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycles 1 and 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part C: Vz of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part D: Vz of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycles 1 and 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part E: Vz of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days)|Part F: Vz of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Vz of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: Vz of TSR-042, Blood samples were planned to be collected at indicated time points., Cycles 1 and 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose; Cycle 2: Pre-dose (each cycle was 21 days)|Part H: Vz of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Vz of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Vz of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Vz of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose; Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part A: AUC at Steady State (AUCss) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part A: AUCss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part B: AUCss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part C: AUCss of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part C: AUCss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part D: AUCss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part E: AUCss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose (each cycle was 21 days)|Part F: AUCss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: AUCss of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: AUCss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: AUCss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: AUCss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: AUCss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: AUCss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part A: Ctau at Steady State (Ctau,ss) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days)|Part A: Ctau,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part B: Ctau,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part C: Ctau,ss of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days)|Part C: Ctau,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part D: Ctau,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part E: Ctau,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose (each cycle was 21 days)|Part F: Ctau,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Ctau,ss of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: Ctau,ss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Ctau,ss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Ctau,ss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Ctau,ss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Ctau,ss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part A: Cmax at Steady State (Cmax,ss) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days)|Part A: Cmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part B: Cmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part C: Cmax,ss of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days)|Part C: Cmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part D: Cmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part E: Cmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose (each cycle was 21 days)|Part F: Cmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Cmax,ss of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: Cmax,ss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Cmax,ss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Cmax,ss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Cmax,ss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Cmax,ss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part A: Time to Reach Maximum Plasma Concentration (Tmax) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part A: Tmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part B: Tmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part C: Tmax of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 1: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose (each cycle was 21 days)|Part C: Tmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part D: Tmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose (each cycle was 21 days)|Part E: Tmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Tmax of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Tmax of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: Tmax of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Tmax of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part H: Tmax of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part I: Tmax of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part I: Tmax of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 1: Pre-dose, 0.5, 1, 2, 3, 24, 48, 96, 168 and 336 hours post-dose (each cycle was 21 days)|Part A: Tmax at Steady State (Tmax,ss) of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days)|Part A: Tmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part B: Tmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part C: Tmax,ss of Niraparib, Blood samples were collected at indicated time points. PK parameters of niraparib were calculated using non-compartmental methods., Cycle 2: Pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose; Cycles 5 and 11: Pre-dose, 2 hours post-dose (each cycle was 21 days)|Part C: Tmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part D: Tmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part E: Tmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose (each cycle was 21 days)|Part F: Tmax,ss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Tmax,ss of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: Tmax,ss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Tmax,ss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Tmax,ss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Tmax,ss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Tmax,ss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part A: Volume of Distribution After Intravenous Administration (Vss) of of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part B: Vss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part C: Vss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part D: Vss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 4: Pre-dose, 0.5, 2, 24, 96, 168, 336 and 504 hours post-dose; Cycles 5 and 11: Pre-dose, 0.5, 2, 24, 96, 168, 336, 504 and 1008 hours post-dose (each cycle was 21 days)|Part E: Vss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose (each cycle was 21 days)|Part F: Vss of TSR-042, Blood samples were collected at indicated time points. PK parameters of TSR-042 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part F: Vss of TSR-022, Blood samples were collected at indicated time points. PK parameters of TSR-022 were calculated using non-compartmental methods., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part G: Vss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Vss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part H: Vss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Vss of TSR-042, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)|Part I: Vss of TSR-022, Blood samples were planned to be collected at indicated time points., Cycle 2: Pre-dose; Cycle 5: Pre-dose, 0.5, 2, 24, 48, 96, 168, and 336 hours post-dose (each cycle was 21 days)
Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part B: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part C: To test the safety and tolerability of combination therapy with Niraparib, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.

Part D: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.

Part E: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part F: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part G: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part H: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part I: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.